ARENA PHARMACEUTICALS INC's ticker is ARNA and the CUSIP is 040047607. A total of 219 filers reported holding ARENA PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 0.44 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $390,000 | +12.1% | 4,200 | -17.6% | 0.01% | 0.0% |
| Q2 2021 | $348,000 | -41.2% | 5,100 | -33.8% | 0.01% | -55.6% |
| Q4 2020 | $592,000 | -24.6% | 7,700 | -26.7% | 0.03% | -34.1% |
| Q3 2020 | $785,000 | +13.4% | 10,500 | -4.5% | 0.04% | +5.1% |
| Q2 2020 | $692,000 | +49.8% | 11,000 | 0.0% | 0.04% | +18.2% |
| Q1 2020 | $462,000 | -85.6% | 11,000 | -88.8% | 0.03% | -81.8% |
| Q4 2019 | $3,213,000 | +1.7% | 98,000 | +42.0% | 0.18% | -5.2% |
| Q3 2019 | $3,158,000 | -8.7% | 69,000 | +16.9% | 0.19% | -9.5% |
| Q2 2019 | $3,459,000 | +15.1% | 59,000 | -11.9% | 0.21% | +13.4% |
| Q1 2019 | $3,004,000 | +57.4% | 67,000 | +36.7% | 0.19% | +44.2% |
| Q4 2018 | $1,909,000 | -15.3% | 49,000 | 0.0% | 0.13% | -2.3% |
| Q3 2018 | $2,255,000 | -7.7% | 49,000 | -47.3% | 0.13% | -9.0% |
| Q2 2018 | $2,443,000 | -29.3% | 93,000 | -35.0% | 0.14% | -34.1% |
| Q1 2018 | $3,457,000 | +25.6% | 143,000 | +76.5% | 0.22% | +27.2% |
| Q4 2017 | $2,752,000 | – | 81,000 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 164,300 | $9,633,000 | 4.86% |
| Atika Capital Management LLC | 230,000 | $13,485,000 | 2.65% |
| DAFNA Capital Management LLC | 93,942 | $5,508,000 | 2.07% |
| PFM Health Sciences, LP | 1,828,378 | $107,198,000 | 2.04% |
| Perceptive Advisors | 1,380,171 | $80,919,000 | 1.86% |
| Eversept Partners, LP | 73,501 | $4,309,364 | 1.21% |
| Partner Investment Management, L.P. | 18,159 | $1,065,000 | 1.13% |
| Rhenman & Partners Asset Management AB | 170,000 | $9,967,000 | 1.10% |
| EMERALD ADVISERS, LLC | 425,510 | $24,948,000 | 1.00% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 388,418 | $22,773,000 | 0.90% |